| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.1 | 0.03 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.03 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.03 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.099 | 0.03 |
| mRNA | JQ-1:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.072 | 0.03 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.03 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | -0.076 | 0.03 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.03 |